Provider review
MEDGm Review: It Tells People of Normal Weight They Are Great Candidates
MEDGm's eligibility answer is the most consequential sentence we read in this sweep. Asked "Will this work for me?", its FAQ replies that you are likely a great candidate at 18 to 74 years old with "a BMI of 20+". A body-mass index of 20 is normal weight. Every GLP-1 weight-loss trial enrolled at 30 and above, or 27 with a weight-related condition — so the threshold this page offers sits below the floor of the entire evidence base.
Answers "will this work for me?" with a yes, at a body-mass index the trials excluded, before any clinician has looked.
Worth trusting if
- You want the dispensing pharmacies named, which they are, with addresses and telephone numbers
- You want a plain statement that compounded medicines are not FDA-approved, which the site gives
Be skeptical if
- You are near a normal body-mass index and reading the FAQ as clinical guidance, because no trial enrolled anyone there
- You take a pre-payment screen calling you a clinical match as a medical opinion, because no clinician has seen you at that point
- You are budgeting from the advertised figure, which is a first-month coupon rate rather than the standing one
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens medgm.org. A link is not a recommendation to take anything.
Provenance
What MEDGm actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — Advertised from $179, which is a first-month rate after an automatically applied coupon; the standing month-to-month rate is $299.
- Compounded tirzepatide injection — Advertised from $279 as a first-month rate; the standing month-to-month rate is $399.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to MEDGm.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from MEDGm’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim reaches past the trials
“Will this work for me? Yes, you are likely a great candidate if you are between 18 and 74 years old and have a BMI of 20+. Our providers offer personalized GLP-1 compounded treatments tailored to your specific health journey.”
Read on the MEDGm site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in adults with a body-mass index of 30 or above, or 27 or above with at least one weight-related condition. Nobody with a body-mass index of 20 was enrolled — the entry criteria excluded them.
The drug works; the sentence about who should take it does not follow from any trial. STEP 1 enrolled 1,961 adults at a body-mass index of 30 or above, or 27 or above with a weight-related condition, and every subsequent trial in the program used the same floor. A body-mass index of 20 is squarely inside the normal range, which means the threshold this FAQ offers sits below the entry criteria of the entire evidence base — a person at 20 would have been screened out of every study the drug's reputation rests on. "Will this work for me?" is answered "Yes" before any clinician has seen anything, and the answer is a marketing sentence occupying the place where a clinical one belongs.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)No trial supports this claim
“STATUS: CLINICAL MATCH. Success probability 100%. Expected response: Strong. [Name]'s GLP-1 prescription plan approved!”
Read on the MEDGm site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks, adults with obesity or overweight and no diabetes. Reported a mean weight reduction, a distribution of responses, and a proportion of participants who did not reach any given threshold. No trial of any drug has reported a success probability of 100%.
Three of these four lines are clinical assertions, and no clinician had made them. When we walked the intake on 1 September 2026 with invented answers, this screen appeared before payment — while the site's own footer says an OpenLoop clinical professional meets the patient AFTER payment to determine whether they qualify. "Success probability 100%" is the part with no defensible reading: SURMOUNT-1 reported a mean, a spread and a share of participants who did not reach a given threshold, and no trial of any drug in any condition has ever reported certainty. "CLINICAL MATCH", "Expected response: Strong" and a plan "approved" are the vocabulary of a clinical decision, produced by a quiz.2
Dispensing chain
Who actually fills your prescription
- RedRock Pharmacy
- Health Warehouse
Read the full account
MEDGm names its dispensing pharmacies, including RedRock Pharmacy in St. George, Utah and Health Warehouse in Florence, Kentucky, with addresses and telephone numbers — real disclosure that most of this market does not offer. The same pharmacies are named by several other sellers we have reviewed; that is a shared vendor set and says nothing about who owns whom, and we draw no such conclusion. The prescribing side is not named at the individual level: the medical practice appears as OpenLoop, and no clinician, medical director or advisory name is published. The site's disclosure of what compounding means is better than most, and worth quoting in full because a shorter excerpt would misrepresent it: "Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved and have not been evaluated for safety, efficacy, or quality." That draws the right line between a facility being inspected and a product being approved.
Read on the MEDGm site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published. What the site does publish, and prominently, is social proof at a scale it does not source: "Join our 120,000+ patients" on the homepage, and named testimonials carrying a VERIFIED badge and specific numbers — one reads "I've lost 38 pounds in just 4 months". The same site's own disclaimer says that materials on the site "may be generated or enhanced using artificial intelligence technologies" and that "no representation or warranty is made regarding the accuracy, completeness, or reliability of such content", and that individuals appearing in advertisements may be actors or artificial intelligence. A badge reading VERIFIED sits on top of content the company explicitly declines to vouch for. Our earlier pass also recorded review counts of 20,000, 23,600 and 13,800 in different places on the site, none sourced and none reconciling with the others.
Read on the MEDGm site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
MEDGm advertises the service as "100% Online — from consult to delivery", and notes separately that telemedicine regulations vary by state and that some states require a live video or telephone consultation before prescribing. No per-state list is published, so a reader cannot tell in advance which applies to them.
Read the full licensing claim
No clinician is named — no prescriber, no medical director, no advisory panel. The medical practice is identified as OpenLoop. The entity is MEDGm, LLC. The site states that a clinical professional meets the patient after payment to determine whether they qualify for a prescription.
Read on the MEDGm site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- It names its dispensing pharmacies with addresses and telephone numbers.
- Its compounding disclosure is accurate and unusually complete — it distinguishes a regulated facility from an approved product in the same sentence.
- It states plainly that compounded medications have not been evaluated for safety, efficacy or quality.
Show 2 more
- It notes that telemedicine rules vary by state and that some states require a live consultation before prescribing.
- No FDA warning letter against MEDGm, LLC or the named pharmacies.
- Its FAQ tells anyone with a body-mass index of 20 or above that they are likely a great candidate — a threshold below the entry criteria of every GLP-1 weight-loss trial.
- That answer appears under the heading "Will this work for me?", where a reader is most likely to treat it as clinical guidance.
- When we walked the intake, a pre-payment screen declared "STATUS: CLINICAL MATCH" and "Success probability 100%" before any clinician had seen anything.
Show 8 more
- No trial of any drug has reported a success probability of 100%, and the trials for these molecules report a distribution of responses including non-responders.
- The site's own footer says a clinical professional determines whether a patient qualifies after payment, which the pre-payment screen pre-empts.
- Testimonials carry a VERIFIED badge and specific weight-loss figures while the site's disclaimer declines to warrant the accuracy of its own content.
- The same disclaimer says individuals in advertisements may be actors or artificial intelligence.
- Patient and review counts are unsourced and do not reconcile with one another.
- The advertised entry prices are first-month coupon rates, not the standing ones.
- No clinician is named anywhere.
- Its peptide-adjacent lines — sleep, sexual health and hair loss — are all marked coming soon and cannot be bought.
Verdict
The bottom line
Two things here are better than the market average: the pharmacies are named, and the compounding disclosure is genuinely accurate. Everything clinical is worse. The FAQ answers whether the drug will work for you with a yes at a body-mass index the trials screened out, and the intake hands you a "clinical match" with a "100% success probability" before a clinician has read a word. Treat both as advertising, because that is what they are, and get an actual clinical opinion before you pay.
Opens medgm.org. A link is not a recommendation to take anything.
The sentence that matters
On MEDGm's GLP-1 page, under a FAQ headed "Will this work for me?":
"Yes, you are likely a great candidate if you are between 18 and 74 years old and have a BMI of 20+."
A body-mass index of 20 is normal weight. The normal range runs from 18.5 to 24.9.
Every GLP-1 weight-loss trial enrolled at 30 or above, or 27 or above with a weight-related condition. STEP 1 randomized 1,961 adults on exactly that criterion. 1 SURMOUNT-1 used the same floor. 2
So a person at a body-mass index of 20 would have been screened out of every study the drug's reputation is built on. The threshold this page offers sits below the floor of the entire evidence base.
That answer also arrives in the worst possible place — under the question a reader asks when they want to know whether a medicine is right for them, phrased as a yes, before any clinician has seen anything.
Full analysis — 3 more sections"Success probability 100%" · The VERIFIED badge · What MEDGm gets right
"Success probability 100%"
When we walked MEDGm's intake with invented answers on 1 September 2026, a screen appeared before payment reading:
STATUS: CLINICAL MATCH
Success probability 100%
Expected response: Strong
"[Name]'s GLP-1 prescription plan approved!"
The site's own footer says an OpenLoop clinical professional meets the patient after payment to determine whether they qualify for a prescription. So at the moment those four lines appear, nobody clinical has looked at anything.
"Success probability 100%" is the line with no defensible reading. SURMOUNT-1 reported a mean reduction, a spread around it, and a share of participants who did not reach any given threshold. No trial of any drug, in any condition, has reported certainty.
(We could not reproduce this screen on 2 September — the quiz requires real answers to advance past its first step, and we reached only medgm.org/glp-1/quiz. The finding above is what our own dated intake walk recorded.)
The VERIFIED badge
From the homepage:
Sarah M. ✓ VERIFIED — "The MEDGm program has truly changed my life. I've lost 38 pounds in just 4 months, and I feel more energetic than I have in years."
And from the same site's disclaimer:
"Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies. No representation or warranty is made regarding the accuracy, completeness, or reliability of such content."
Plus a note that individuals appearing in advertisements may be actors or artificial intelligence.
The badge says VERIFIED. The disclaimer says the company will not vouch for it. Both are on the site.
The counts have the same problem: the homepage says "Join our 120,000+ patients", and our earlier pass found review totals of 20,000, 23,600 and 13,800 in different places, none sourced, none reconciling.
What MEDGm gets right
It names its dispensing pharmacies — RedRock Pharmacy and Health Warehouse among them — with addresses and telephone numbers. Most sellers in this market name none.
And its compounding disclosure is genuinely accurate. It is worth quoting whole, because a shorter excerpt would misrepresent it:
"Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved and have not been evaluated for safety, efficacy, or quality."
That is the correct distinction between a facility being inspected and a product being approved, and a lot of this market never draws it.
Questions
Frequently asked questions
Is a BMI of 20 really enough to qualify?
It is what MEDGm's FAQ says, and no trial supports it. A body-mass index of 20 sits inside the normal range of 18.5 to 24.9. Every GLP-1 weight-loss trial enrolled at 30 or above, or 27 or above with a weight-related condition, so someone at 20 would have been excluded from all of them. Treat that answer as advertising and get a clinical opinion.
Does the site really say my success probability is 100%?
That is what our intake walk recorded on September 1, 2026, on a screen shown before payment — alongside "STATUS: CLINICAL MATCH", "Expected response: Strong" and a plan marked approved. The site's own footer says a clinical professional determines whether you qualify after payment, so nobody clinical has seen anything at that point. No trial of any drug has ever reported a 100% success probability.
Are the testimonials real?
We cannot tell, and neither, on its own account, can the company. Testimonials carry a VERIFIED badge and specific figures — one claims 38 pounds in four months — while the site's disclaimer says its materials may be generated or enhanced using artificial intelligence, makes no representation as to their accuracy, and says individuals in advertisements may be actors or artificial intelligence.
What will I actually pay?
More than the advertised figure after the first month. The entry prices shown before intake are first-month rates produced by an automatically applied coupon; the standing month-to-month rates are substantially higher for both molecules.
Which pharmacy fills the prescription?
MEDGm names several, including RedRock Pharmacy and Health Warehouse, with addresses and telephone numbers — genuine disclosure that most sellers here do not offer. It does not say which one fills which order. The same pharmacies are named by several other companies in this market; that is a shared vendor set and tells you nothing about ownership.
Can I buy a peptide here?
No. The sleep, sexual health and hair loss lines are all marked coming soon and none can be purchased. Only the GLP-1 products are actually for sale.
Glossary
Key terms
Show definitions
- Trial entry criteria
- The rules deciding who could join a study. They matter because a drug's results describe the people who were enrolled — someone outside those criteria was not tested, whatever the drug does in general.
- Body-mass index
- Weight relative to height. Roughly 18.5 to 24.9 is the normal range, 25 to 29.9 overweight, and 30 and above obesity. GLP-1 weight-loss trials enrolled at 30 and above, or 27 and above with a weight-related condition.
Compare
Others selling what MEDGm sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off MEDGm's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults, entry at BMI ≥30 or ≥27 with at least one weight-related comorbidity. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults, same entry floor; reported a mean reduction, a distribution of responses and a proportion not reaching each threshold. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.